Abelson murine leukemia viral oncogene homolog 1 messenger RNA (ABL1 mRNA) (ABL1 mRNA)

ABL1 mRNA is the messenger RNA transcript of the Abelson murine leukemia viral oncogene homolog 1 gene, which encodes a non-receptor tyrosine kinase essential for cellular processes such as growth, survival, and DNA damage response (NCBI Gene, ID: 25). In hematological malignancies, most notably Chronic Myeloid Leukemia (CML), the ABL1 gene undergoes a reciprocal translocation with the BCR gene to form the BCR-ABL1 fusion gene, resulting in a chimeric mRNA that translates into a constitutively active oncoprotein (UniProt, P00519). This mRNA is a critical therapeutic target for emerging RNA-based modalities, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which aim to degrade the transcript and silence the oncogenic signal at the pre-translational level (PubMed, PMID: 25613577). While current clinical standards utilize tyrosine kinase inhibitors (TKIs) like Imatinib to target the protein product, mRNA-directed therapies are being investigated to bypass resistance caused by kinase domain mutations (PubMed, PMID: 30232345). Furthermore, the precise quantification of BCR-ABL1 and ABL1 mRNA levels via real-time quantitative PCR is the gold standard for monitoring treatment efficacy and detecting minimal residual disease in clinical practice (NCCN Guidelines, 2024).

Other names

c-ABL mRNAABL mRNAProto-oncogene c-Abl mRNABCR-ABL1 fusion mRNAJTK7 mRNAAbelson tyrosine-protein kinase 1 mRNA

RNA interference (RNAi) or antisense-mediated RNase H cleavage of the mRNA transcript to prevent the translation of the ABL1 or BCR-ABL1 tyrosine kinase protein; alternatively, the mRNA serves as the template for protein products targeted by competitive and allosteric tyrosine kinase inhibitors.